Hoffmann-La Roche
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria: * Body weight \>= 40kg * Agreement to adhere to the contraceptive requirements UC Specific Inclusion Criteria: * Confirmed diagnosis of UC with supportive clinical, endoscopic, and histopathological evidence * Active UC confirmed by endoscopy (flexible sigmoidoscopy or colonoscopy) extending \>=15 cm from the anal verge * Moderately to severely active UC, defined as an modified Mayo score of 5 to 9 points, including a Mayo endoscopic subscore of 2 or 3, confirmed through centrally read endoscopy Exclusion Criteria: Inflammatory Bowel Disease (IBD) Exclusion Criteria:…
Afimkibart will be administered as per the schedule defined in the protocol.
Caffeine will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Warfarin will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Omeprazole will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Dextromethorphan will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Midazolam will be administered orally as part of a CYP cocktail per the schedule defined in the protocol.
Vitamin K will be administered orally as a rescue medication following warfarin administration per the schedule outlined in the protocol.